Kissei’s Materiality

Kissei Pharmaceutical leverages its business activities to provide continuous value based on its Management Philosophy, which is to “contribute to society through high-quality, innovative pharmaceutical products” and “serve society through our employees.” One of the basic policies of its five-year medium-term management plan, PEGASUS, is to “promote ESG and the SDGs.” Under this policy, the Company is working to achieve sustainability in terms of society and the earth’s environment, which is the ultimate goal of the SDGs. As part of this effort, we have once again plotted issues on two axes—relevance to company business and impact on stakeholders—to narrow down issues of importance. Based on the results, we have identified a series of priority issues (materiality) for the Company to focus its initiatives, which will contribute to the achievement of the SDGs.

Process for Identifying Materiality

  • STEP1

    Identify social and internal issues, making reference to international guidelines*

  • STEP2

    Have the heads of 35 departments prioritize the issues via an in-Company survey after receiving SDG training

  • STEP3

    Narrow down the number of priority issues through dialogues with external experts regarding the survey results

  • STEP4

    Have the SDGs Promotion Committee and the Board of Directors identify materiality

  • STEP5

    Revise materiality based on changes in the business environment and constructive dialogues with stakeholders

* SDGs, SASB Standards, GRI Standards, Access to Medicine Index.

The Seven Categories of Materiality (Priority Issues)

Based on our Management Philosophy, we consider it our mission and most pressing issue to contribute to the health and medical care of people around the world by providing ethical drugs and other high-quality, innovative pharmaceutical products. For patients suffering from illnesses to be able to use our products with peace of mind, it is highly important that we provide a steady supply of high-quality items coupled with appropriate information.

Therefore, we have created three categories of materiality related to business activities:

Development and provision of products useful to society Steady supply of high-quality products Communication with medical professionals and patients

We have also created four categories of materiality related to our management base, which supports the aforementioned business activities. These categories are “strengthening and enhancement of governance”; “creation of a fulfilling workplace environment”; “environmental initiatives,” aimed at making the earth’s environment sustainable; and “social contribution as a good corporate citizen,” which centers on social development in the local area of Nagano where Kissei’s head office is situated.

Kissei’s Materiality

Main SDGs related to the seven categories Description of materiality Key initiatives
Materiality related to Kissei’s business activities Development and provision of products useful to society
Development of innovative products (drugs, foods) We contribute to the health and medical care of people around the world by providing ethical drugs and other high-quality, innovative pharmaceutical products developed by the Company or through partnerships. ・Drug discovery initiatives ・Promotion of clinical development projects ・Promotion of licensing activities and overseas development
Contribution to scientific technology We contribute toward greater health and welfare by making patents and dissertations for innovative technology created through pharmaceutical research, and by open innovation with academic institutions and other entities. ・Joint research with academia and other pharmaceutical companies ・Participation in consortiums sponsored by the Japan Pharmaceutical Manufacturers Association ・Provision of research grants through the Kanzawa Medical Research Foundation
Steady supply of high-quality products
Quality control and steady supply and procurement We build manufacturing and quality control systems that comply with the latest laws, regulations, and guidelines, procure environmentally friendly materials, and work to provide a steady supply of products in recognition of the fact that our products are related to people’s very lives. ・Formulation and implementation of the “Stable Supply Manual” ・COVID-19-related countermeasures ・Implementation of the Kissei Pharmaceutical Quality System
Communication with medical professionals and patients
Promote proper product usage (drugs, foods) We provide accurate information backed by science, understanding that offering proper information and promoting proper usage is essential for demonstrating the maximum value of our products. ・Promotion of activities to provide appropriate medical information ・Creation of a sales system for rare disease treatments ・Introduction of AI Detail ・Immediate provision of safety information via the safety information provision system
Improve customer satisfaction and provide patient support We contribute to medical treatment by offering the solutions that medical professionals and patients really need. ・Operation of the medicine consultation window ・Operation of a patient-oriented website
Materiality related to Kissei’s management base Strengthening and enhancement of governance
Strengthen governance We have positioned strengthening corporate governance as an important management issue for the continued improvement of corporate value, and we are working to create a system that can address changes inside and outside the Company quickly and flexibly. ・Formulation and implementation of the Kissei Basic Policy on Corporate Governance ・Appointment of a female director ・Increase of the number of outside directors
Risk management We promote the smooth execution of corporate activities by properly managing risks that may hinder the realization of our Management Philosophy and the completion of our management plans and mounting an appropriate response to any risks that manifest. ・Creation of a risk management system ・Development and update of business continuity plans to ・include disaster and pandemic countermeasures
Compliance We practice compliance when conducting corporate activities, understanding that this is fundamental to the sound development of the Company and earning stakeholder trust. ・Implementation of compliance program ・Establishment of a whistleblowing and consultation system (Kissei Hotline) ・Consideration given to animal welfare when conducting experimentation on animals
Creation of a fulfilling workplace environment
Human resource cultivation We respect the individuality of each employee and provide a variety of opportunities for employees to develop their skills, focusing on individual abilities and aptitudes in an effort to develop human resources who can contribute to the development of the Company and society. ・Implementation of rank-based and job-specific training ・Support for self-development ・Establishment of interview system for skill and career development
Promote diversity and gender equality We are striving to improve the Company’s working environment in terms of hiring practices, working styles, our human resource system, and other aspects to ensure that a wide range of employees can demonstrate a variety of abilities, based on the idea that when employees with different modes of thinking and value systems can recognize and inspire each other, they can add dynamism and creativity to a company. ・Initiatives to cultivate the next generation (Platinum Kurumin, etc.) ・Initiatives to promote the success of women ・Prevention of discrimination and harassment ・Recruitment of people with disabilities
Enhance workplace environment We will create worthwhile workplace environment that gives employees a strong sense of motivation as work-style reforms and the response to COVID-19 bring major changes to working conditions. ・Recognition under the 2021 Certified Health & Productivity Management Outstanding Organizations Recognition Program (Large Enterprise Category) ・Promotion of work–life balance ・Initiatives related to occupational health and safety and maintaining employee health
Environmental initiatives
Waste management and resource recycling We work to promote the conservation of a sustainable environment through the effective use of resources, preventing pollution and reducing environmental impact. ・Maintenance of environmental management systems (acquisition of ISO 14001 certification, etc.) ・Implementation of environment conservation activities (management of chemical substances, etc.) ・Priority purchasing of green products
Initiatives toward biodiversity We take care to ensure that our business activities do not adversely affect biodiversity and ecosystems and take action accordingly. ・Proper management of research and clinical trials that involve genetically modified organisms ・Proper management over purchasing reagents (confirmation of whether reagents fall under the Cartagena Act)
Climate change countermeasure We promote environmental management that acknowledges that climate change is a risk factor, with the goal of sustainable growth for society and the Company, and in accordance with the Japan’s Carbon Neutrality Declaration. ・Continued reduction of CO2 emissions ・Promotion of energy-saving measures and climate change countermeasures
Social contribution as a good corporate citizen
Participate in social contribution activities We contribute to the sustainable development of society as an intrinsic part of our corporate activities. Moreover, we actively participate in social contribution activities and endeavor to realize our Management Philosophy as a corporate citizen and a member of society. ・Contribution to culture, the arts, and sports (support in exchange for naming rights, support for activities such as the Seiji Ozawa Matsumoto Festival, and the Matsumoto Yamaga Football Club) ・Participation in local cleanup activities and offering factory and research institute tours ・Donations to child welfare facilities and assistance for natural disasters